NKNavgeet Kaur

Navgeet Kaur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Navgeet Kaur has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis and Evaluation of Coumarin Chalcone Derivatives as DNA Gyrase Inhibitors

    by Sumita Kumari, Amit Sharma, Sonia Yadav

    The purpose of this work was assessing in vitro antimicrobial effects of recently synthesised coumarin chalcone derivatives against various microbial strains. A scheme of coumarin chalcone hybrids were designed, synthesised and characterised their structures by spectral studies such as infrared, nuclear magnetic resonance and mass spectrometry and evaluated for their antimicrobial potential against different strains. In silico designing carried out by molecular docking technique by targeting DNA gyrase protein receptor with PDB ID: 6m1j. All the compounds showed greater binding energy range from -8.4Kcal/mol to -8.9kcal/mol than reference drug ciprofloxacin. Microbial resistance is most challenging issue for all world. To defeat this problem the well diffusion assay method used for assessing antimicrobial profile, demonstrated that most of compounds exhibited remarkable antibacterial and antifungal activity with zones of inhibition in mm. Potential candidates as antimicrobials are 5c, 5e, 5g and 5h with zones of inhibition against B. Subtills, S. aureus, E. coli and P. aeruginosa (5.56±0.179, 5.58±0.449, 4.94±0.811, 4.82±0.378; 7.25±0.191, 6.14±0.496, 5.55±0.496, 5.41±0.421; 6.36±0.024, 6.27±0.029, 5.99±0.666, 6.04±0.432; 5.93±0.118, 4.94±0.016, 6.58±0.029, 5.94±0.119) respectively. Compound 3d exhibited highest antimicrobial potential against C. albicans (7.92±0.389) and S. aureus (7.25±0.191). It is concluded that the potential of synthesised derivatives could be more effective in microbial resistance.


  • Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer

    by Navgeet Kaur, Anju Goyal, Rakesh K. Sindhu

    The importance of monoclonal antibodies in oncology has increased drastically following the discovery of Milstein and Kohler. Since the first approval of the monoclonal antibody i.e. Rituximab in 1997 by the FDA, there was a decline in further applications but this number have significantly increased over the last three decades for various therapeutic applications due to the lesser side effects in comparison to the traditional chemotherapy methods. Presently, numerous monoclonal antibodies have been approved and many are in cue for the approval as a strong therapeutic agent for treating hematologic malignancies and solid tumors. The main target checkpoints for the monoclonal antibodies against cancer cells include EGFR, VEGF, CD and tyrosine kinase which are overexpressed on malignant cells. Other immune checkpoints like CTLA-4, PD-1 and PD-1 receptor targeted by the recently developed antibodies increases the immune system capability in destroying the cancerous cells. Here in this review, mechanism of action, uses and target points of the approved mAbs against cancer have been abridged.